Immunologic monitoring during and after OKT3 therapy

C. F. Shield, Douglas Norman

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Immunologic monitoring should be undertaken during and for 6 weeks after OKT3 treatment. CD3 absolute cell determinations should be obtained three times per week during therapy. A progressive increase of the absolute CD3 cell count above 10/μL is suggestive of an inadequate OKT3 serum level, most often due to an early antimurine response. Weekly posttherapy antimurine response should be determined. The presence or absence of an antimurine response can be suggestive of a successful response to a second therapeutic course of OKT3.

Original languageEnglish (US)
Pages (from-to)120-124
Number of pages5
JournalAmerican Journal of Kidney Diseases
Volume11
Issue number2
StatePublished - 1988

Fingerprint

Immunologic Monitoring
Muromonab-CD3
Therapeutics
Cell Count
Serum

ASJC Scopus subject areas

  • Nephrology

Cite this

Immunologic monitoring during and after OKT3 therapy. / Shield, C. F.; Norman, Douglas.

In: American Journal of Kidney Diseases, Vol. 11, No. 2, 1988, p. 120-124.

Research output: Contribution to journalArticle

@article{7c693904279d4ce18de67cb05e7e08d7,
title = "Immunologic monitoring during and after OKT3 therapy",
abstract = "Immunologic monitoring should be undertaken during and for 6 weeks after OKT3 treatment. CD3 absolute cell determinations should be obtained three times per week during therapy. A progressive increase of the absolute CD3 cell count above 10/μL is suggestive of an inadequate OKT3 serum level, most often due to an early antimurine response. Weekly posttherapy antimurine response should be determined. The presence or absence of an antimurine response can be suggestive of a successful response to a second therapeutic course of OKT3.",
author = "Shield, {C. F.} and Douglas Norman",
year = "1988",
language = "English (US)",
volume = "11",
pages = "120--124",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Immunologic monitoring during and after OKT3 therapy

AU - Shield, C. F.

AU - Norman, Douglas

PY - 1988

Y1 - 1988

N2 - Immunologic monitoring should be undertaken during and for 6 weeks after OKT3 treatment. CD3 absolute cell determinations should be obtained three times per week during therapy. A progressive increase of the absolute CD3 cell count above 10/μL is suggestive of an inadequate OKT3 serum level, most often due to an early antimurine response. Weekly posttherapy antimurine response should be determined. The presence or absence of an antimurine response can be suggestive of a successful response to a second therapeutic course of OKT3.

AB - Immunologic monitoring should be undertaken during and for 6 weeks after OKT3 treatment. CD3 absolute cell determinations should be obtained three times per week during therapy. A progressive increase of the absolute CD3 cell count above 10/μL is suggestive of an inadequate OKT3 serum level, most often due to an early antimurine response. Weekly posttherapy antimurine response should be determined. The presence or absence of an antimurine response can be suggestive of a successful response to a second therapeutic course of OKT3.

UR - http://www.scopus.com/inward/record.url?scp=0023871413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023871413&partnerID=8YFLogxK

M3 - Article

C2 - 3277402

AN - SCOPUS:0023871413

VL - 11

SP - 120

EP - 124

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 2

ER -